Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled study of subcutaneous onercept in moderate to severe plaque psoriasis
2004-000530-37Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Oct 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of onercept in plaque psoriasis (4 arms), sponsored by Merck Serono. Primary endpoint: PASI 75 response at week 12. Started Oct 2004; status: completed.
02
Drugs
onercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2004-000530-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000530-37.